|
gptkbp:instance_of
|
gptkb:biotechnology
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:acquisition_year
|
gptkb:2018
|
|
gptkbp:approves
|
Chondro Celect in Europe
Cx601 in Europe
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:business_model
|
biopharmaceuticals
|
|
gptkbp:ceo
|
gptkb:Eduardo_Bravo
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Argentina
gptkb:Australia
gptkb:Brazil
gptkb:Canada
gptkb:Chile
gptkb:Japan
gptkb:Mexico
gptkb:South_Korea
gptkb:United_States
ongoing
Phase II
Phase III
analyzed
Phase I
published
various diseases
Chondro Celect for cartilage repair
Cx601 for complex perianal fistulas
|
|
gptkbp:collaboration
|
Universities and research institutions
|
|
gptkbp:collaborations
|
academic institutions
international research organizations
biotech companies
|
|
gptkbp:community_engagement
|
active
|
|
gptkbp:community_outreach
|
engaged
|
|
gptkbp:financial_performance
|
publicly reported
|
|
gptkbp:financial_reports
|
published quarterly
|
|
gptkbp:focus
|
gptkb:Cell
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:has_advisory_board
|
established
|
|
gptkbp:head_of_state
|
ongoing
|
|
gptkbp:headquarters
|
gptkb:Leuven,_Belgium
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ti Genix NV
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:instruction_set
|
diverse
|
|
gptkbp:invention
|
multiple
cell therapy products
|
|
gptkbp:investment
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Series_B
active
Venture capital
held regularly
institutional investors
Series C
R& D investments
|
|
gptkbp:key_people
|
gptkb:Johan_Van_Hoof
|
|
gptkbp:location
|
gptkb:Belgium
|
|
gptkbp:market
|
conducted
cell-based therapies
|
|
gptkbp:market_cap
|
approximately €100 million
|
|
gptkbp:market_launch
|
planned.
|
|
gptkbp:market_position
|
strong
|
|
gptkbp:marketing_strategy
|
global expansion
|
|
gptkbp:number_of_employees
|
50-100
|
|
gptkbp:partnership
|
gptkb:Takeda_Pharmaceutical_Company
strategic
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:product
|
gptkb:Chondro_Celect
gptkb:Cx601
continuous
allogeneic cell therapy
autologous cell therapy
|
|
gptkbp:product_approvals
|
achieved
|
|
gptkbp:product_type
|
advanced therapy medicinal product
|
|
gptkbp:publications
|
numerous
|
|
gptkbp:region
|
gptkb:Europe
|
|
gptkbp:regulatory_compliance
|
gptkb:European_Medicines_Agency
strict
|
|
gptkbp:research_areas
|
gptkb:Cell
multiple
orthopedics
gastroenterology
|
|
gptkbp:research_focus
|
regenerative medicine
orthopedic surgery
|
|
gptkbp:safety
|
prioritized
|
|
gptkbp:strategic_goals
|
gptkb:expansion
|
|
gptkbp:subsidiary
|
gptkb:Ti_Genix_USA,_Inc.
|
|
gptkbp:supply_chain
|
managed
|
|
gptkbp:sustainability_initiatives
|
implemented
|
|
gptkbp:traded_on
|
gptkb:Euronext_Brussels
|
|
gptkbp:treatment
|
monitored
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.tigenix.com
|
|
gptkbp:year
|
December 31
|
|
gptkbp:bfsParent
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:bfsLayer
|
5
|